Para realizar su inscripción, haga clic en el botón a continuación y complete sus datos
Quiero inscribirmeCOSTO DE INSCRIPCIÓN
Socio AAMR con cuota al día al 31/03/2026 - SIN CARGO
No socios - AR$ 80.000
Residentes - Enfermeros - Técnicos - SIN CARGO
INVITADOS INTERNACIONALES
Dra. Noemí Reguart
España
Dra. Noemí Reguart
España
Dr. Noemi Reguart graduated from the University of Medicine Lleida in 1995. She
then finished her postgraduate studies and oncology fellowship at the Hospital Clinic
in Barcelona (2001). She earned a PhD in molecular lung cancer during her predoctoral
work at the University of California, San Francisco (2004–2005). She has been working as a thoracic oncologist at the Hospital Clinic Barcelona's Department of
Medical Oncology since 2008. In addition, she is an Associate Professor at the University of Barcelona's School of Medicine, where she is committed to both undergraduate and graduate education. Dr. Reguart has been instrumental in the development and institutional recognition of the Thoracic Oncology Unit, at the Hospital Clinic, which she is in charge of as of the year 2020.
Lung cancer research has always been a top goal for Dr. Reguart. She accomplishes this by combining her usual duties and patient care with translational research. She has taken part in a variety of trials investigating cutting-edge therapies for people with lung cancer, including their design and patient enrollment. She also oversees a Thoracic Research Group, part of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), that is tasked with finding new biomarkers that could be used as lung cancer predictive indicators and as a gauge of treatment response. Working with other teams undertaking groundbreaking research, she specifically integrates and assesses cutting-edge technology to ensure that it can be properly translated in the clinic.
Dr. Reguart has authorship on numerous publications in the field of NSCLC and targeted medicine, is co-author of several national and international guidelines for the treatment of lung cancer and is an active opinion leader on networks (Twitter@NReguart). Prof. Reguart holds memberships in several national and international scientific organizations including the Spanish Lung Cancer Group (SLCG), the Spanish Association for Cancer Research (ASEICA), the European Organization for Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC) (all currently actives). She is currently chair of the EORTC Lung Cancer Group for Small Cell Lung Cancer (2021-) and Committee Member for the IASLC Communications Committee (2019-). She also served as a member of the Board of Directors of the SLCG (2007–2019), Faculty Member of ESMO (2021-) and ASEICA (2014-2018). She has been invited to join various national and international conferences’ scientific committees (ASEICA, SLCG, WCLC, ELCC, ESMO), several working groups (i.e., Oncology-PRO Working Group, ESMO), and has served as both a guest speaker and keynote speaker at numerous national and international conferences. Dr. Reguart has chaired the ELCC 2023 and IASLC-WCLC 2025. Dr. Reguart is a referee or reviewer for several indexed international journals and competitive national and international research calls.
Dr. Sergio Call
España
Dr. Sergio Call
España
Sergi Call nació en Barcelona en 1979 y se licenció en Medicina por la Universidad Autónoma de Barcelona en 2003. Realizó la especialidad de Cirugía Torácica en el Hospital Universitario
MútuaTerrassa, donde obtuvo el título de especialista en 2010.
Es Profesor Asociado de Anatomía en la Universidad Autónoma de Barcelona desde 2014 y Profesor Asociado de Cirugía Torácica en la Universidad de Barcelona desde 2020. En 2017 obtuvo el grado de Doctor por la Universidad de Barcelona, con la tesis titulada “Estadificación y reestadificación prequirúrgica de máxima certeza en el tratamiento quirúrgico del carcinoma broncogénico”, calificada con Sobresaliente Cum Laude.
Desarrolla su actividad asistencial como cirujano torácico en el Hospital Universitario MútuaTerrassa, donde actualmente ejerce como Jefe Clínico del Servicio de Cirugía Torácica. Cuenta con la acreditación como Fellow del European Board of Thoracic and Cardiovascular Surgeons por la European Union of Medical Specialists (UEMS), y participa activamente en sociedades científicas nacionales e internacionales.
Sus principales áreas de interés incluyen la estadificación quirúrgica del cáncer de pulmón, la cirugía mínimamente invasiva, las metástasis pulmonares y la oncología torácica. Es autor de más de 20 capítulos de libro en el ámbito de la cirugía torácica y la oncología torácica, así como autor o coautor de más de 50 publicaciones en revistas internacionales indexadas.
Dr. Juan P. Wisnivesky
Estados Unidos
Dr. Juan Pablo Wisnivesky
Estados Unidos
Juan Pablo Wisnivesky is the Drs. Richard and Mortimer Bader Professor of Medicine and Chief of the Division of General Internal Medicine at the Icahn School of Medicine at Mount Sinai in New York City. An experienced health services researcher, Dr. Wisnivesky’s work focuses on lung cancer epidemiology, lung cancer screening, and patient-oriented outcomes. He earned his MD from the University of Buenos Aires School of Medicine and his MPH and Doctor of Public Health degree from the Joseph L. Mailman School of Public Health at Columbia University in New York City.
Dr. Wisnivesky has been awarded numerous grants from the National Institutes of Health and the Agency for Healthcare Research and Quality to support his research. He serves as the director of a federally funded Cancer Prevention and Control T32 Training Program, which focuses on improving cancer prevention and outcomes among priority populations. His research utilizes large national datasets and administrative claims data to investigate the epidemiology, diagnosis, treatment, and outcomes of lung cancer.
Dr. Wisnivesky is engaged in global research education as faculty in the American Thoracic Society’s Methods in Epidemiologic, Clinical, and Operations Research Program, which trains early-career investigators across Latin America. Additionally, he is an active member of the American Society for Clinical Investigation and is a member of the National Committee on Vital and Health Statistics.
Dr. Ignacio Wistuba
Estados Unidos
Dr. Ignacio Wistuba
Estados Unidos
Ignacio I. Wistuba, MD, is Chair and Senior Member of the Department of Translational Pathology at Moffitt Cancer Center, Tampa, Florida, USA. Until May 2025, he was Professor and Chair of the Department of Translational Molecular Pathology with joint appointment in the Department of Thoracic/Head and Neck Medical Oncology, and co-director of the Institute of Personalized Cancer Therapy (IPCT) at the University of Texas MD Anderson Cancer Center. Between 2019 and 2022 he served as Head of the Division of Pathology and Laboratory Medicine at MD Anderson. He is a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC).
Dr. Wistuba’s major research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and other solid tumors. He has co-authored over 850 papers in peer-reviewed journals and several book chapters. He led several extramural peer-review funded (NCI, DoD, V-Foundation, and Texas CPRIT) programmatic research programs. His research interests also include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy, and identifying molecular markers associated with lung cancer and other solid tumors development, progression and metastasis development using annotated human specimens.
AVANCES PROGRAMA PRELIMINAR
Inmunoterapia perioperatoria
Small Cell, actualizaciones en primera y segunda línea
EPOC y cáncer de pulmón
Re estadificación post quimio e inmunoterapia
Screening en cáncer pulmonar
Rol del patólogo en el tratamiento neoadyuante
Presente y futuro de la biopsia líquida
Re-estadificación con VAMLA resultados preliminares
Novedades en segundas líneas post-quimio-inmunoterapia
Enfoque actual de la patología molecular
Inteligencia Artificial Aplicada a la Patología
COMITÉ ORGANIZADOR y CIENTÍFICO
SPONSORS
AUSPICIOS ACADÉMICOS
